tirzepatide vs wegovy comparison vs. Ozempic: What To Know Wegovy (Semaglutide) vs Mounjaro (Tirzepatide)

Research shows that maintaining dietary discipline after discontinuation preserves significantly more weight loss results than returning to pre-treatment eating patterns

The compounding pharmacy will assign a specific expiration date based on their stability testing data

Tirzepatide (Mounjaro, Zepbound) is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management and chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity

While its effectiveness in weight loss is impressive, some side effects should be considered: Gastrointestinal Issues: Nausea, vomiting, diarrhea, and constipation are common, especially when starting treatment

When both receptors are activated simultaneously, combined effect on digestive system stronger than with a GLP-1 drug alone

Restart timing depends on delivery method and breastfeeding plans